The COVID-19 vaccine maker is jumping into CAR-M technology with its deal with Carisma Therapeutics.
Novavax (NASDAQ: NVAX) is arriving more than a year after market leaders Pfizer and Moderna to the coronavirus vaccine finish line. Novavax soared 2,700% in 2020. As of today, Novavax's vaccine has won authorization from more than 30 countries.
Moderna (NASDAQ: MRNA) has come a long way in just two years. The biotech company developed one of the leading coronavirus vaccines in about nine months -- and has since made billions of dollars in vaccine revenue and profit.